Bethesda, MD--Cheers! A new research report appearing in the October 2011 issue of The FASEB Journal (https:/
"Resveratrol is a potential pharmacological tool to be exploited when breast cancer become resistant to the hormonal therapy," said Sebastiano Andò, a researcher involved in the work from the Faculty of Pharmacy at the University of Calabria in Italy.
To make this discovery, Andò and colleagues used several breast cancer cell lines expressing the estrogen receptor to test the effects of resveratrol. Researchers then treated the different cells with resveratrol and compared their growth with cells left untreated. They found an important reduction in cell growth in cells treated by resveratrol, while no changes were seen in untreated cells. Additional experiments revealed that this effect was related to a drastic reduction of estrogen receptor levels caused by resveratrol itself.
"These findings are exciting, but in no way does it mean that should people go out and start using red wine or resveratrol supplements as a treatment for breast cancer," said Gerald Weissmann, M.D., Editor-in-Chief of The FASEB Journal. "What it does mean, however, is that scientists haven't finished distilling the secrets of good health that have been hidden in natural products such as red wine."
Receive monthly highlights from The FASEB Journal by e-mail. Sign up at http://www.
FASEB comprises 24 societies with more than 100,000 members, making it the largest coalition of biomedical research associations in the United States. FASEB enhances the ability of scientists and engineers to improve--through their research--the health, well-being and productivity of all people. FASEB's mission is to advance health and welfare by promoting progress and education in biological and biomedical sciences through service to our member societies and collaborative advocacy.
Details: Francesca De Amicis, Francesca Giordano, Adele Vivacqua, Michele Pellegrino, Maria Luisa Panno, Donatella Tramontano, Suzanne A. W. Fuqua, and Sebastiano Andò. Resveratrol, through NF-Y/p53/Sin3/HDAC1 complex phosphorylation, inhibits estrogen receptor α gene expression via p38MAPK/CK2 signaling in human breast cancer cells. FASEB J. 2011 25:3695-3707; doi:10.1096/fj.10-178871 ; http://www.